SPHS Sophiris Bio Inc.

2.25
+0.01  (0%)
Previous Close 2.24
Open 2.21
Price To book 5.11
Market Cap 67750094
Shares 30,111,153
Volume 140,489
Short Ratio 21.30
Av. Daily Volume 167,486

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b six-month biopsy data for all patients in 1Q 2018 with final biopsy data due 4Q 2018.
Topsalysin (PRX302)
Localized low to intermediate risk prostate cancer
Phase 3 primary endpoints met - November 2015. Second Phase 3 trial dependent on funding.
Topsalysin (PRX302)
Benign prostatic hyperplasia

Latest News

  1. Sophiris Bio Secures up to $10 Million in Term Loans from Silicon Valley Bank
  2. Sophiris Bio to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
  3. SPHS: Phase 2b Trial of Topsalysin in Prostate Cancer Underway
  4. Sophiris Bio Reports Second Quarter Financial Results and Key Corporate Highlights
  5. Sophiris Bio Added to Russell Microcap Index
  6. Sophiris Bio Announces that the First Patient Has Been Dosed in Phase 2b Study of Topsalysin in Patients with Clinically Significant Localized Prostate Cancer
  7. Sophiris Bio Provides Update on Phase 2b Study of Topsalysin in Localized Prostate Cancer
  8. SPHS: Dosing of Patients in Phase 2b Trial of Topsalysin in Prostate Cancer to Initiate Soon
  9. Sophiris Bio Reports First Quarter Financial Results and Key Corporate Highlights
  10. Sophiris Bio Presents Topsalysin Data from Phase 2a Proof-of-Concept Study in Localized Prostate Cancer at 112th American Urological Association (AUA) Meeting
  11. Sophiris Bio to Present at 16th Annual Needham Healthcare Conference
  12. Sophiris Bio Reports Fourth Quarter and Full Year 2016 Financial Results and Key Corporate Highlights
  13. Topsalysin Data from Successful Phase 2a Localized Prostate Cancer Study to be Presented at the 32nd European Association of Urology Congress
  14. Sophiris Bio to Present at 29th Annual ROTH Conference
  15. Sophiris Bio to Webcast Live Presentation at BetterInvesting's Virtual Investor Conference
  16. Life Sciences & Healthcare Investor Conference & Webinar: Nasdaq and OTCQX Companies Present February 2nd
  17. Sophiris Bio, Inc. :SPHS-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016